RxDoctor Payments Data

Daniel Dubose, MD

Otolaryngology/Facial Plastic Surgery · Sonora, CANPI 1164437471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $219 and has fallen 73.9% since, to $57 in 2025. That places this record below the midpoint for otolaryngology/facial plastic surgery clinicians in CA, where the typical reported total is $1,073.

$1,094in general payments, 2019–2025

Across 41 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$249
  • Acclarent, Inc$210
  • Stryker$195
  • Sanofi$143
  • Intersect ENT, Inc.$106
  • Medtronic$48
  • plus $144 from 5 others

What the payments were for

  • Food & beverage$1,094100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,094 in reported general payments places this provider in the 50th percentile of 102 otolaryngology/facial plastic surgery providers in California.

See all otolaryngology/facial plastic surgery providers in California

Medicare billing

Part B allowed, 2024
$199,857
Medicare patients
971
Services billed
3,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$68,958
Dupixent SyringeDupilumab11$40,485
Ipratropium Bromide257$10,433
Fluticasone Propionate339$5,809
Azelastine Hcl58$1,798
Dexamethasone11$824
Mometasone Furoate32$669
Pilocarpine Hcl11$640
Montelukast Sodium54$601
Albuterol Sulfate HfaAlbuterol Sulfate14$492
Omeprazole42$426
Levothyroxine Sodium45$387
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav28$335
Famotidine17$258
Clindamycin Hcl15$215

Paid to pharmacies, not to this prescriber.

Other otolaryngology/facial plastic surgery in Sonora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →